RxDoctor Payments Data

William Lyman, MD

Colon & Rectal Surgery · Charlotte, NCNPI 1104212711

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.5%), education and food and beverage — rather than concentrated in one kind of arrangement. Intuitive Surgical accounts for 90.6% of it on its own, with 11 other manufacturers making up the rest. Reporting peaked in 2019 at $3,545 and has fallen 98.9% since, to $40 in 2025.

$11,465in general payments, 2019–2025

Across 65 payments — averaging $176.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$10K
  • Medtronic$301
  • Smith+Nephew$257
  • Innovation Technologies Inc$150
  • Boston Scientific$113
  • Johnson & Johnson$89
  • plus $170 from 6 others

What the payments were for

  • Travel & lodging$5,67349%
  • Food & beverage$2,18919%
  • Education$3,59431%
  • Gifts$90%

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$11,465 in reported general payments places this provider in the 85th percentile of 27 colon & rectal surgery providers in North Carolina.

See all colon & rectal surgery providers in North Carolina

Medicare billing

Part B allowed, 2024
$69,888
Medicare patients
167
Services billed
396

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LinzessLinaclotide12$9,474
Metronidazole37$125
Ciprofloxacin Hcl32$116
Oxycodone Hcl33$100
Ondansetron OdtOndansetron18$81
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$74
Ondansetron Hcl13$29

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLinzess$15$9,47412 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 27 colon & rectal surgery providers in North Carolina.

Other colon & rectal surgery in Charlotte

See the full list for North Carolina

Where these figures come from

Is this you, or does something look wrong? →